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Abstract: The aim of this study was to compare the imaging symptoms and microscopic findings in females with lobular
neoplasia (LN) found on biopsy. 1,478 women who underwent primary open biopsy or surgical excision after percutane-
ous biopsy were reviewed. In 24 of them (1.6%), LN was found. In four patients, excisional biopsy with hook-wire
localization was done primarily due to the radial scar. In 20 females, surgical excision of BIRADS 4 lesion was per-
formed because of the presence of LN in specimens from the vacuum-assisted or core-needle percutaneous biopsy.
Postoperative pathologic findings were compared to the radiological symptoms. In 13 women, LN did not produce
any radiological symptoms and was an additional histologic finding existing near the other lesion: fibroadenoma and
radial scar. In none of these lesions was an invasive cancer noticed. In one single patient, ductal carcinoma in situ was
observed in the other segment of the breast. Invasive ductal cancer developed in the contralateral breast in one patient.
In 11 patients, LN was diagnosed due to radiological symptoms produced by itself. In this group, the invasive lobular
cancer was found in seven lesions (64%). Our finding suggests that LN producing suspicious radiological symptoms
can be a different biologic type of this lesion when compared asymptomatic LN diagnosed which is usually found on
biopsy as additional microscopic pathology. Symptomatic LN is probably associated with a higher potential of malig-
nant transformation. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 417–424)
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Introduction
Lobular neoplasia (LN) covers the entire spectrum
of lobular disease, ranging from minimal lobular in-
volvement to maximum distention of acini in several
lobular units, with or without pagetoid involvement
of terminal ducts. Cytologically, the cells of LN have
a uniform appearance with distinct cell borders.
Pathologically, LN (Figure 1) is characterized by
a solid proliferation of loosely cohesive, uniform small
cells that fill and distend the acini of a terminal duct
lobular unit [1]. In recent decades, there has been
a four-fold increase in its incidence, especially in post-
-menopausal women aged 50–59 years [2]. LN has been
typically regarded as a marker of an increased risk of
invasive breast cancer (IBC) rather than as a true pre-
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cursor lesion [3]. This concept is also supported by
some more recent studies [4]. However, its direct as-
sociation with invasive lobular carcinoma (ILC) has
been postulated by others [5].
The aim of this study was to examine the radio-
logical symptoms and microscopic findings, compar-
ing them to the prevalence, type, and site of the inva-
sive cancer in females with LN found on biopsy.
Material and methods
Patients. 1,478 women who underwent primary open biop-
sy or surgical excision after minimal invasive percutaneous
biopsy between 2004 and 2008 were studied. In 24 of them
(1.6%), LN was diagnosed. All these lesions were classified
as BIRADS 4. Mean (median, range) patient age was 53.8
± 3.6 years (53, 37–69). Neither breast cancer history nor
family history was present. Hormone replacement therapy
was being given to five (21%) women. Mean (median, range)
clinical tumor size was 12.8 ± 0.9 mm (13, 7–22). Palpable
mass was found in two (8%) females. Status of the estrogen
receptor was positive in 21 (88%) patients.
Management. In each case, excision of the lesion was done.
In four women, image-guided excisional biopsy with hook-
-wire localization was done primarily due to the radial scar
without mass. In 20 females, surgical excision lesion was
performed for histologic assessment of the completely re-
moved lesion because of the presence of LN (with fibroade-
noma in nine cases) in specimens from the hand-held vacu-
um-assisted or core-needle percutaneous biopsy. Postopera-
tive histologic evaluation was done and pathologic findings
were compared to the radiological symptoms. A comparison
between groups with LN radiologically symptomatic- and
asymptomatic-diagnosed as additional histologic finding near
the other symptomatic lesion is presented in Table 1.
Open biopsy and wire localization. Two lesions were pre-
sented as palpable tumors. For the other non-palpable le-
sions, needle localization of the lesion was carried out un-
der local anesthesia. It was performed using an Accura BLN
device (Medical Device Technologies Inc, Gainesville, FL,
USA; distribution in Europe by PBN Medicals, Stenlose,
Denmark) under imaging guidance. After the needle was
placed and its position was confirmed, the hook-wire was
deployed and the same radiological view was obtained to
confirm the wire position.
Minimal invasive biopsy. Percutaneous minimal-inva-
sive biopsy performed under local anesthesia was made
as an alternative to open biopsy for adequate pathologi-
cal examination of the lesion and for optimal treatment
planning if further surgical excision was needed. For two
palpable tumors, 14-gauge core needle biopsy was per-
formed using an Angiotech device 14 ga × 12 cm (Med-
ical Device Technologies Inc). Eighteen women with non-
-palpable lesions were referred for image-guided proce-
dures. For five lesions with a diameter equal to or great-
er than 15 mm, core needle biopsy (as above) was carried
out under ultrasonography guidance. For 13 patients with
smaller abnormalities, vacuum-assisted biopsy was of-
fered. In five of these cases (two with microcalcifications
and three with architectural distortion) stereotactic vac-
uum-assisted biopsy was done with the patient prone on
a designated table with the 11-gauge Mammotome de-
vice MST 11 (Mammotest Plus/S, Fisher Imaging, Den-
ver, CO, USA). In the other eight (with sonographic mass
lesion) ultrasound-guided biopsy was performed using
11-gauge hand-held probe MHH 11 (Ethicon Endo-Sur-
gery Europe, Norderstedt, Germany). For lesions im-
aged in both mammography and sonography, biopsy
under ultrasound guidance was the preferred option in
our institution.
Pathology. All hematoxylin and eosin stained slides of
formalin-fixed and paraffin-embedded tissue blocks previ-
ously diagnosed in double assessment as lobular carcinoma
in situ (LCIS) or atypical lobular hyperplasia (ALH) were
Table 1. Comparison between groups with radiologically asymptomatic and symptomatic LN




positive, n (%)/negative, n (%) 3 (23%)/10 (77%) 2 (18%)/9 (82%)
Palpable mass
absent, n (%)/present, n (%) 12 (92%)/1 (8%) 10 (91%)/1 (9%)
Pathologic tumor size [mm]
mean/median/range 13.8/13.2/9–22* 14.1/13.5/8–21
Estrogen receptor status
positive, n (%)/negative, n (%) 11 (85%)/2 (15%) 10 (91%)/1 (9%)
*Diameter of symptomatic lesion coexisting with asymptomatic LN
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re-evaluated by a supervising pathologist (A.H.) LN was
diagnosed according to the well-defined histological crite-
ria [6]. For a diagnosis of LCIS, all the acini had to be filled,
and at least half of them distended by round or oval nor-
mochromatic cells that were similar in appearance and place-
ment to each other. ALH lesions were defined as lobular pro-
liferations that exhibited some, but not all, of the features of
LCIS, including incomplete involvement of acini within the
lobular unit. Focal LN was diagnosed if one lobule or less
was involved (Figure 2). When more than one lobule was
involved (Figure 3), the case was classified as extensive LN.
When there was any doubt about the origin of the lesion (lob-
ular vs. ductal) E-cadherin staining was performed.
Results
LN without any radiological symptoms
In 13 women, LN did not produce any radiological
symptoms and was an incidental histologic finding
existing near the other lesion: fibroadenoma in nine
cases (Figures 4 and 5) and radial scar in four (Fig-
ure 6). All these cases were classified as focal LN. In
none of these lesions was an ILC noticed. In one of
these patients (8%), ductal carcinoma in situ (DCIS)
was found in the other segment of the ipsilateral breast
and in another one (8%), infiltrating ductal cancer
(IDC) developed in the contralateral breast.
LN diagnosed due to itself with
imaging techniques
In 11 females, LN was diagnosed with imaging tech-
niques as BIRADS 4 lesion due to radiological symp-
toms produced by itself (Figures 7–9). There were six
lesions with mass, three with architectural distortion,
and two with microcalcifications. All these lesions
were classified as extensive LN. In this group, ILC
was found in seven lesions (64%). Six of them were
diagnosed as mass lesions, one as architectural dis-
tortion. No other malignancy was observed in the ipsi-
or contralateral breast in these women. None of the
lesions associated with microcalcifications was histo-
logically upgraded after surgical excision. Findings are
presented in Table 2.
Discussion
The reported relative risk, compared to women in the
general population, for developing subsequent IBC
after an incidental finding of LN in a biopsy, ranges
in long-term follow-up studies from 3.0–4.2-fold
[2, 7] to 5.9–12.0-fold [8, 9]. Approximately 50% of
them are believed to occur more than 15 years after LN
Figure 1. Lobular neoplasia — the solid proliferation of
loosely cohesive, uniform small cells fill and distend the acini
of a terminal duct lobular unit. (H&E, magnification × 200)
Figure 2. Focal lobular neoplasia with one lobule in one
core involved. (H&E, magnification × 100)
Figure 3. Diffuse LN with multiple lobules involved in one
core. (H&E, magnification × 20)
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diagnosis, while 38% occur more than 20 years later.
The risk over 15 to 20 years is 10% to 20% (5). It is
spread over long periods, being about 0.5% to 1%
per year, which seems to be a consequence of the rel-
atively low proliferative rate of these lesions [9].
LN has been typically regarded as a non-surgical
disease and viewed as a marker of an increased risk
of IBC, rather than as a true precursor lesion [3].
Some more recent papers have shown that women
with LN found on breast biopsy without concurrent
malignancy are at increased risk for the subsequent
development of IBC, either ipsi- or contralateral,
Figure 4. Lobular neoplasia as incidental histologic finding
associated with fibroadenoma. Photo with hand-held
11-Gauge vacuum-assisted biopsy probe. The same patient
as on Figure 5
Figure 5. Lobular neoplasia as incidental histologic finding
associated with fibroadenoma. The same patient as on
Figure 4
Figure 6. Lobular neoplasia as incidental histologic finding
next to radial scar lesion. Photo of excised specimen with
hook-wire
ductal or lobular [10–14]. However, the results of oth-
er studies with long-term follow-ups showed an ap-
proximately two-fold increased incidence of IBC in
the ipsilateral breast compared to the contralateral
one in women with LN diagnosed in minimal-inva-
sive biopsy [15, 16]. Nearly 50% of the subsequent
cancers are categorized as tumors with good progno-
sis, i.e.: ILC, tubular, tubulo-lobular, ring cell, med-
ullary [16]. Our findings confirm the concept that LN
is an indicator of higher risk for more significant dis-
ease (DCIS or IBC), but only in regard to asymptom-
atic focal LN coexisting with another radiologically
symptomatic lesion.
On the other hand, there is growing evidence that
LN is a direct precursor of ILC. Recent studies
showed that three out of four cases of IBC occur in
the ipsilateral breast and the subsequent cancer is
usually an infiltrating lobular carcinoma (ILC) or has
a prominent lobular component [17–20]. The percent-
age of ILC, regarding the type of IBC diagnosed af-
ter LN, has also been reported over 50% by others
[21, 22] while only 5–10% of IBCs without a history
of LN are of lobular histology [22].
Findings from the SEER study of 45,871 patients
showed that women with LCIS are more likely to de-
velop ipsilateral IBC (0.73% vs. 0.54%), are 5.3-fold
more likely to develop ILC, and are 0.8-fold less like-
ly to develop invasive ductal cancer compared to wom-
en with ductal carcinoma in situ [23]. LN is present in
up to 12% of early IBC [24] and is 25-fold more likely
to be associated with ILC than with ductal one [25].
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Figure 7. Radiologically symptomatic LN presented as mass lesion classified as BIRADS 4
Figure 8. Radiologically symptomatic LN presented in
sonography as mass lesion classified as BIRADS 4. Photo
with hand-held 11-Gauge vacuum-assisted biopsy probe.
The same patient as on Figure 9
Figure 9. Radiologically symptomatic LN presented in
sonography as mass lesion classified as BIRADS 4.
Photo without probe. The same patient as on Figure 8
Table 2. Imaging and pathologic findings
Group Lesion histology Radiological presentation Other breast malignancy,
ipsi- or contralateral
Asymptomatic LN + fibroadenoma, n = 9 Mass, n = 9 DCIS in ipsilateral breast
LN + radial scar, n = 4 Architectural distortion, n = 4 IDC in contralateral breast
Symptomatic LN only, n = 4 Mass, n = 6
LN + ILC , n = 7 Architectural distortion, n = 3 None
Microcalcifications, n = 2
DCIS — ductal carcinoma in situ; IDC — invasive ductal cancer; ILC — invasive lobular cancer
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The ten-year cumulative incidence rate of ipsilateral
breast cancer recurrence after breast-conserving ther-
apy for IBC can be five-fold increased when concur-
rent LN is present. Most recurrent tumors are inva-
sive and are located in the vicinity of the primary IBC
[25]. The risk of concurrent ILC within the radiolog-
ically symptomatic LN was as high as 64% in our study,
and the lack of the other ipsi- and contralateral IBC
support the precursor-product relationship between
these lesions. Genetic studies have attempted to prove
a genetic correlation between LCIS and ILC when
they appear synchronously and to clarify whether LN
serves as a precursor for the development of invasive
lobular cancer or is a marker for advanced genetic
changes in breast tissue.
However, the answer to the question of whether
LN is a premalignant lesion or a heterogenous dis-
ease is still not definitively determined [26].
There are no accepted guidelines for the manage-
ment of LN diagnosed on core-needle or vacuum-as-
sisted breast biopsy [27]. There was no increased risk
of IBC in the site of lesion in subsequent surgical ex-
cision of LN diagnosed in biopsy in some studies
[28–30]. On the contrary, in other series, the rate of
LN upgraded to IBC or DCIS ranged from 17% to
42% [31–36]. Esserman et al. noticed ILC after exci-
sion only in two of 26 patients with LN diagnosed on
core [37]. In these cases, ILC was associated with dif-
fuse LN, and no ILC was observed when LN was di-
agnosed as focal.
These findings are partly similar to ours, indicat-
ing that excision may not be necessary when only fo-
cal LN is found on core biopsy. Moreover, it suggests
that symptomatic diffuse LN can be a direct precan-
cerous lesion for ILC. Lechner et al. in a multi-insti-
tutional study of 32,424 lesions in which minimal-in-
vasive breast biopsy was performed found 34% of LN
lesions diagnosed at percutaneous biopsy to be ma-
lignant at excision [38]. The increased risk of under-
estimation of LN diagnosed in biopsy is significantly
associated with higher BIRADS category, mass le-
sions (vs. microcalcifications), and use of a core bi-
opsy (vs. vacuum-assisted) [39]. In the study by Bau-
er et al. IBC was noticed on surgical biopsy only in
one patient with LN associated with benign fibrocys-
tic disease diagnosed on core [40]. However, this rate
increased to 27% when radial scar, atypical hyper-
plasia, intraductal papilloma or phyllodes tumor were
found with LN on percutaneous biopsy.
Due to these discrepancies, many authors recom-
mend an individual approach, claiming that LN should
be excised when: ductal involvement is found [41];
LN is associated with atypical ductal hyperplasia [42];
residual microcalcifications are seen [17]; at least ten
lobules are involved [34]; another high-risk or bor-
der-line lesion is present [43, 44]; it is not possible to
exclude DCIS despite E-cadherin immunochemistry
[44]; and LN is pleomorphic or with necrosis [44, 45].
Final management based on a consideration of the
outcomes at one’s own institution is recommended
by some as the most reasonable option [17].
Middleton et al., describing the MD Anderson
experience with LN on core-needle biopsy, found IBC
in 35% of symptomatic lesions [45]. Similarly to us,
most of them (83%) were seen as mass-forming le-
sions. The need for re-biopsy of all atypical hyperpla-
sia lesions is also emphasized by others [46]. In our
study, only LN diagnosed as BIRADS 4 lesions were
analyzed. Based on the recent reports, the positive
predictive value for malignancy is 44–61% for LN seen
as BIRADS 3 tumors and 85–90% for LN viewed as
BIRADS 4 lesion [47, 48]. It is also increased for LCIS
and tumors larger than 2 cm when compared to ALH
and smaller lesions: 57.1% vs. 7.1%, and 100% vs.
31.2%, respectively [49]. Interestingly, there was sig-
nificantly increased risk of IBC in the site of mass-
-forming LN reported in the study from Nottingham
University Hospital, but the authors claimed that it
was the result of biopsy missing the radiologically
symptomatic lesion next to incidental LN [44]. When
LN is not a direct precancerous lesion, the possible
reason of the increased risk of IBC is the misdiagno-
sis in pathological assessment. Histologic differenti-
ation of LN and DCIS is usually not difficult, but ar-
eas of overlap exist. In follow-up surgery, up to 20%
of all LN and up to 50% of mass-forming LN can be
upgraded to DCIS [50]. In addition, the fragmenta-
tion of lesion after minimal-invasive biopsy increases
the challenge to diagnose these lesions correctly [50].
Some authors believe the available data remains
inadequate to make a definitive determination of the
best management policy for LN diagnosed on percu-
taneous biopsy [51]. Others claim that LN should be
always regarded as a high risk lesion and that wide
excision after core biopsy is needed [52].
Because of a high rate of ILC within radiological-
ly symptomatic LN in our series, subsequent removal
with clear margins is the preferred option in our in-
stitution. Our findings support the concept that ILC
can develop directly from the clonal expansion of the
cells present in LN lesions. Further studies are need-
ed to clarify this possible precursor-product relation-
ship. More research is required to understand the
long-term pathogenic implications of LN diagnosis
in minimal-invasive breast biopsy.
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